Boehringer Ingelheim Chemicals Closing Virginia API Manufacturing Facility
The closure will impact 240 employees through a multistage process starting in December 2013.
Boehringer Ingelheim Chemicals Inc. (BICI) will close its Petersburg, Virginia plant at the end of 2014. According to an Aug. 15, 2013 BICI press release, the facility will continue normal operations through the remainder of 2013 and phase out operations the following year. The closure will impact 240 employees through a multistage process starting in December 2013.
The Petersburg facility manufactures active ingredients for the pharmaceutical industry. BICI’s parent company, Boehringer Ingelheim, conducted a review of its current manufacturing capabilities worldwide, as well as needs in the industry, and determined that it had more capacity than the marketplace can sustain. BICI considered selling the facility but was unable to find a buyer. The company said it will begin working with its customers immediately to ensure a smooth transition to new suppliers.
Source: Boehringer Ingelheim Chemicals
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
